Article Text

ASSA13-11-15 Efficacy and Safety of Fondaparinux During Thrombolytic Therapy in Acute ST-Elevation Myocardial Infarction Patients
  1. Zhao Xin,
  2. Han Ya-Ling,
  3. Wang Xiao-Zeng,
  4. Xu Bai-Ge
  1. Shenyang Northern Hospital


Objective To assess efficacy and safety of Fondaparinux during thrombolytic therapy in acute ST-elevation myocardial infarction patients.

Methods From November 2011 to April 2012, patients with acute ST-elevation myocardial infarction and pain to hospital time within 6 hours were received thrombolytic therapy by recombinant tissue-type plasminogen activator (rt-PA). Before thrombolytic therapy, patients were randomly assigned to Fondaparinux group (2.5mg, n = 30) or standard heparin group (60U/kg, maximum 4000U, n = 32). Coronary angiography or PCI were performed at 90min after initiating study drugs. Primary endpoints of the trial were the rate of TIMI grade 3 flow at 90minutes. other endpoints included incidence of all cause mortality at in-hospital, 30 days and 6 months, major bleeding and minor bleeding at in-hospital, 30d and 6 months.

Results (1) There were no difference of primary endpoints (Fondaparinux group vs heparin group, 64.6% vs 62.5%, p = 0.158). (2) PCI procedure: Successful rate of immediate post-procedure was 100%. The average number of stents per patient was 1.1 ± 0.4 and the average diameter and length of stent were (3.0 ± 0.7) and (21.2 ± 3.1) mm. (3) Safety: No significant difference existed between fondaparinux group and heparin group in major bleeding (in-hospital, 30d and 6 months, p > 0.05). However, the fondaparinux group had a lower prevalence of mild bleeding than heparin group (in-hospital and 30d, p ± 2.1months. ➀ Fondaparinux group had a lower mortality of in-hospital but has no statistical difference (p > 0.05). ➁ Mortality at 30d and 6 months were all similar in Fondaparinux treated patients compared to heparin treated patients (p > 0.05).

Conclusions Fondaparinux, which can reduce the time of reperfusion with decreasing mortality and mild haemorrhage, is feasible and safe for the patients with STEMI during thrombolysis therapy.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.